Advertisement

Topics

Companies Related to "Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer" [Most Relevant Company Matches] RSS

22:40 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Rollover Study Weekly Paclitaxel 181339 Patients With Advanced" Companies 1–25 of 6,100+

Relevant

Genta Incorporated

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead com...


BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...


Phyton Biotech, LLC

Phyton Biotech, LLC is a global supplier of high quality paclitaxel and docetaxel API. The company has development and manufacturing facilities near Hamburg, Germany and Vancouver, Canada. One of the largest producers of paclitaxel and docetaxel in the world, Phyton has been inspected by EDQM, EMA, FDA, KFDA, and TGA. Phyton also substantially focus...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

NewsRx

The New York Times news service called the company "the world's largest producer of weekly health information," and Pharmaceutical Executive magazine echoed this observation: "NewsRx is one of the world’s largest weekly health information providers in print, with such titles as Cancer Weekly, AIDS Weekly, and Women's Health Weekly." NewsRx publishes 103 titles, and in its history, has produced ...

Swiss Medical Weekly

Swiss Medical Weekly, which began publication in 1871 as "Correspondenz-Blatt für Schweizer Aerzte", is now an international peer-reviewed medical journal.Throughout 130 years of its existence, the Swiss Medical Weekly has played a decisive role in Swiss clinical research.To reach more European authors and more readers worldwide, we have switched from our multilingual tradition to an English-only...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Advanced Biomedical Research, Inc

Advanced Biomedical Research, Inc. (ABR) Corporate Headquarters is located in the heart of New Jersey's pharmaceutical R&D corridor in Princeton, NJ. ABR is a full service CRO offering an integrated package of customized services including clinical study protocol design, project management and study monitoring, quality assurance auditing, medical safety monitoring, biostatistics and clinical data ...

ViGor Biotics Inc.

Plant made pharmaceutical manufacturer and distributor of generic bulk API Paclitaxel

Advanced ICU Care

Advanced ICU Care® is a medical service company that provides high-quality remote critical care to patients in the intensive care units (ICU) of community hospitals. Through experienced clinicians, supported by cutting-edge telemedicine technology and a process improvement program, Advanced ICU Care provides continuous ICU patient monitoring and improved care and safety outcomes to critically ill...

ADVANCED VIRAL RESEARCH CORP

Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), established in the mid-1980s, and headquartered in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing, and bringing to market new and effective therapies for many serious diseases and disorders. With the commitment of expert leadership and skilled research scientists, ADVR is ag...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Vitrolife AB (publ)

The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been ...

The Center for Advanced Medicine and Clinical Research

Since 1996, The Center for Advanced Medicine & Clinical Research has helped people with "untreatable conditions" and those who cannot be cured by traditional medicine. Under the direction of Dr. Rashid A. Buttar, the Center implements a holistic approach, incorporating mainstream medicine as well as various disciplines and treatments with advanced medical concepts and techniques to help patients r...

Hanmi Pharmaceutical co., Ltd.

Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-can...

Neuro-Hitech

Neuro-Hitech is focused specifically on the development and commercialization of next-generation therapies against proven targets for neurodegenerative diseases. The company’s signature offering, Huperzine A is being tested for efficacy in the treatment of Alzheimer's disease and the company has plans to study other degenerative disorders such as vascular dementia, mild cognitive impairment and ...

CTECH Labs Edwar Technology

CTECH Labs Edwar Technology developed the prototype for ECVT in 2004 and continues to research and study new applications for the technology. CTECH Labs has collaborated with world universities and centers for research and development, including Ohio State University (U.S.), National Natural Science Laboratory of Japan, and Universiti Kebangsaan (Malaysia)...

The German Breast Group and Celgene Corporation

GBG is a large independent academic network of over 500 study centers in Germany with the world- wide largest experience in conducting neoadjuvant breast cancer trials. Since 1998, with joined forces from AGO-B, over 10.000 patients participated in the neoadjuvant “Gepardo” trial series. GBG has recruited at totality of over 35.000 patients to tr...


More From BioPortfolio on "Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks